Journal of Renal Nutrition
Volume 20, Issue 1 , Pages 52-62 , January 2010

Report of a Pilot, Double-Blind, Placebo-Controlled Study of Megestrol Acetate in Elderly Dialysis Patients With Cachexia

  • Shing-Shing Yeh, PhD, MD

      Affiliations

    • Geriatric Division, Department of Medicine, Northport Veteran Affairs Medical Center, Northport, New York
    • Corresponding Author InformationAddress reprint requests to Shing-Shing Yeh, PhD, MD, Geriatric Division, Department of Medicine, Northport Veteran Affairs Medical Center, Box 111, Northport, NY 11768.
    • ,
  • Mozhdeh Marandi, MD

      Affiliations

    • Department of Neurology, Wake Forest University Health Sciences, Winston-Salem, North Carolina
    • ,
  • Henry C. Thode Jr., PhD

      Affiliations

    • Department of Emergency Medicine, State University of New York at Stony Brook, Stony Brook, New York
    • ,
  • Daniel M. Levine, PhD

      Affiliations

    • Rogosin Institute, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York
    • ,
  • Thomas Parker, PhD

      Affiliations

    • Rogosin Institute, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York
    • ,
  • Troy Dixon, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, Northport Veteran Affairs Medical Center, Northport, New York
    • ,
  • Michael W. Schuster, MD

      Affiliations

    • Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York

References 

  1. Hakim RM, Levin N. Malnutrition in hemodialysis patients. Am J Kidney Dis. 1993;21:125–137
  2. Acchiardo SR, Moore LW, Latour PA. Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int. 1983;24(Suppl):S199–S203
  3. Kaminski M, Lowrie E, Rosenblatt S, Haase T. Malnutrition is lethal, diagnosable, and treatable in ESRD patients. Transplant Proc. 1991;23:1810–1815
  4. Marckmann P. Nutritional status and mortality of patients in regular dialysis therapy. J Intern Med. 1989;226:429–432
  5. Bergstroem J. Anorexia in dialysis patients. Semin Nephrol. 1996;6:222–229
  6. Bologa R, Levine D, Parker T, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia and mortality in hemodialysis patients. Am J Kidney Dis. 1998;32:107–114
  7. Yeh SS, Hafner A, Chang CK, Levine DM, Parker TS, Schuster MW. Risk factors relating blood markers of inflammation and nutritional status to survival in cachectic geriatric patients in a randomized clinical trial. J Am Geriatr Soc. 2004;52:1708–1712
  8. von Roenn JH, Murphy RL, Weber KM, Williams LM, Weitzman SA. Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1988;109:840–841
  9. Loprinzi CL, Bernath AM, Schaid DJ, et al. Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Oncology. 1994;51(Suppl 1):2–7
  10. Von Roenn JH. Randomized trials of megestrol acetate for AIDS-associated anorexia and cachexia. Oncology. 1994;51(Suppl 1):19–24
  11. Campbell WW, Trappe TA, Jozsi AC, Kruskall LJ, Wolfe RR, Evans WJ. Dietary protein adequacy and lower body versus whole body resistive training in older humans. J Physiol (Lond). 2002;542:631–642
  12. Robert S, Zarowitz B, Hyzy R, Eichenhorn M, Peterson E, Popovich JJ. Bioelectrical impedance assessment of nutritional status in critically ill patients. Am J Clin Nutr. 1993;57:840–844
  13. Chertow GM, Lazarus JM, Lew NL, Ma L, Lowrie EG. Bioimpedance norms for the hemodialysis population. Kidney Int. 1997;52:1617–1621
  14. Chertow GM, Lowrie EG, Wilmore DW, et al. Nutritional assessment with bioelectrical impedance analysis in maintenance hemodialysis patients. J Am Soc Nephrol. 1995;6:75–81
  15. Essig M, Vrtovsnik F. How to evaluate body composition in chronic kidney disease?. Nephrol Ther. 2008;4:92–98
  16. Sullivan DH. Risk factors for early hospital readmission in a select population of geriatric rehabilitation patients: the significance of nutritional status. J Am Geriatr Soc. 1992;40:792–798
  17. Presland JD, Dowson M, Cairns S. Changes of motor drive, cortical arousal and perceived exertion following prolonged cycling to exhaustion. Eur J Appl Physiol. 2005;95:42–51
  18. Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr. 2005;15:345–355
  19. Boccanfuso JA, Hutton M, McAllister B. The effects of megestrol acetate on nutritional parameters in a dialysis population. J Ren Nutr. 2000;10:36–43
  20. Raj DS, Dominic EA, Pai A, et al. Skeletal muscle, cytokines, and oxidative stress in end-stage renal disease. Kidney Int. 2005;68:2338–2344
  21. Rysz J, Banach M, Cialkowska-Rysz A, et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cell Mol Immunol. 2006;3:151–154
  22. Pertosa G, Marfella C, Tarantino EA, et al. Involvement of peripheral blood monocytes in haemodialysis: in vivo induction of tumour necrosis factor alpha, interleukin 6 and beta 2-microglobulin. Nephrol Dial Transplant. 1991;6(Suppl 2):18–23
  23. Simmons EM, Himmelfarb J, Sezer MT, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004;65:1357–1365
  24. Girndt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Buschenfelde KH, Fleischer B. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int. 1995;47:559–565
  25. Tarakcioglu M, Erbagci AB, Usalan C, Deveci R, Kocabas R. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Mediators Inflamm. 2003;12:15–19
  26. Borazan A, Aydemir S, Sert M, Yilmaz A. The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels. Mediators Inflamm. 2004;13:361–364
  27. Borazan A, Ustun H, Ustundag Y, et al. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels. Mediators Inflamm. 2004;13:201–204
  28. Ralph P, Nakoinz I, Sampson-Johannes A, et al. IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol. 1992;148:808–814
  29. Lapinet JA, Scapini P, Calzetti F, Perez O, Cassatella MA. Gene expression and production of tumor necrosis factor alpha, interleukin-1beta (IL-1beta), IL-8, macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and gamma interferon-inducible protein 10 by human neutrophils stimulated with group B meningococcal outer membrane vesicles. Infect Immun. 2000;68:6917–6923
  30. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med. 1993;178:2207–2211
  31. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S. Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med. 1994;179:1695–1699
  32. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol. 1993;11:165–190
  33. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765
  34. Girndt M, Ulrich C, Kaul H, Sester U, Sester M, Kohler H. Uremia-associated immune defect: the IL-10-CRP axis. Kidney Int. 2003;24(Suppl):S76–S79
  35. Raj DS , Moseley P, Dominic EA, et al. Interleukin-6 modulates hepatic and muscle protein synthesis during hemodialysis. Kidney Int. 2008;73:1054–1061
  36. Raj DS, Dominic EA, Wolfe R, et al. Coordinated increase in albumin, fibrinogen, and muscle protein synthesis during hemodialysis: role of cytokines. Am J Physiol Endocrinol Metab. 2004;286:E658–E664
  37. Raj DS , Adeniyi O, Dominic EA, et al. Amino acid repletion does not decrease muscle protein catabolism during hemodialysis. Am J Physiol Endocrinol Metab. 2007;292:E1534–E1542
  38. Ruderman NB, Keller C, Richard AM, et al. Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes. 2006;55(Suppl 2):S48–S54
  39. Panichi V, Taccola D, Rizza GM, et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron Clin Pract. 2006;102:c51–c58
  40. Painter P, Messer-Rehak D, Hanson P, Zimmerman S, Glass N. Exercise capacity in hemodialysis, CAPD, and renal transplant patients. Nephron. 1986;42:47–51
  41. Frey S, Mir A, Lucas M. Visceral protein status and caloric intake in exercising versus nonexercising individuals with end-stage renal disease. J Ren Nutr. 1999;9:71–77
  42. Moros MT, Moros J, Ros R, Villarroya A, Coarasa A. Effects of exercise in the elderly with chronic renal failure. Rev Med Univ Navarra. 1995;39:136–140
  43. Sullivan DH, Roberson PK, Smith ES, Price JA, Bopp MM. Effects of muscle strength training and megestrol acetate on strength, muscle mass, and function in frail older people. J Am Geriatr Soc. 2007;55:20–28
  44. Loprinzi CL, Jensen MD, Jiang NS, Schaid DJ. Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc. 1992;67:1160–1162
  45. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–799
  46. Movilli E, Bossini N, Viola BF, et al. Evidence for an independent role of metabolic acidosis on nutritional status in haemodialysis patients. Nephrol Dial Transplant. 1998;13:674–678

PII: S1051-2276(09)00215-5

doi: 10.1053/j.jrn.2009.08.005

Journal of Renal Nutrition
Volume 20, Issue 1 , Pages 52-62 , January 2010

Article Tools

* Image Usage & Resolution